Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

TROFOSFAMIDE for Metastatic malignant melanoma: Side Effects & Safety Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

There are 32 adverse event reports in the FDA FAERS database where TROFOSFAMIDE was used for Metastatic malignant melanoma.

Most Reported Side Effects for TROFOSFAMIDE

Side Effect Reports % Deaths Hosp.
Acute myeloid leukaemia 18 16.5% 9 1
Myelodysplastic syndrome 18 16.5% 9 1
Product use in unapproved indication 16 14.7% 0 2
Off label use 15 13.8% 2 1
Neutropenia 14 12.8% 1 6
Anaemia 13 11.9% 0 0
Dyspnoea 12 11.0% 0 7
Oedema 10 9.2% 0 0
Pleural effusion 10 9.2% 0 5
Hepatosplenomegaly 9 8.3% 0 0
Hyperleukocytosis 9 8.3% 1 0
Rhabdomyosarcoma recurrent 9 8.3% 2 0
Thrombocytopenia 9 8.3% 0 0
Neoplasm progression 8 7.3% 2 0
Acute kidney injury 7 6.4% 1 5

Other Indications for TROFOSFAMIDE

Diffuse large b-cell lymphoma (13) Alveolar rhabdomyosarcoma (12) Langerhans' cell histiocytosis (11) Angioimmunoblastic t-cell lymphoma (6) Product used for unknown indication (6) Hodgkin's disease (5) Lymphoma (5)

Other Drugs Used for Metastatic malignant melanoma

NIVOLUMAB (4,628) IPILIMUMAB (4,430) DABRAFENIB (3,885) PEMBROLIZUMAB (2,742) TRAMETINIB DIMETHYL SULFOXIDE (2,031) VEMURAFENIB (1,848) TRAMETINIB (1,604) COBIMETINIB (898) ENCORAFENIB (865) BINIMETINIB (841)

Related Pages

TROFOSFAMIDE Full Profile All Metastatic malignant melanoma Drugs TROFOSFAMIDE Demographics TROFOSFAMIDE Timeline